6
|
Masiero M, Simões F, Han H, Snell C, Peterkin T, Bridges E, Mangala L, Wu SY, Pradeep S, Li D, Han C, Dalton H, Lopez-Berestein G, Tuynman J, Mortensen N, Li JL, Patient R, Sood A, Banham A, Harris A, Buffa F. A core human primary tumor angiogenesis signature identifies the endothelial orphan receptor ELTD1 as a key regulator of angiogenesis. Cancer Cell 2013; 24:229-41. [PMID: 23871637 PMCID: PMC3743050 DOI: 10.1016/j.ccr.2013.06.004] [Citation(s) in RCA: 235] [Impact Index Per Article: 21.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/18/2012] [Revised: 02/27/2013] [Accepted: 06/06/2013] [Indexed: 11/24/2022]
Abstract
Limited clinical benefits derived from anti-VEGF therapy have driven the identification of new targets involved in tumor angiogenesis. Here, we report an integrative meta-analysis to define the transcriptional program underlying angiogenesis in human cancer. This approach identified ELTD1, an orphan G-protein-coupled receptor whose expression is induced by VEGF/bFGF and repressed by DLL4 signaling. Extensive analysis of multiple cancer types demonstrates significant upregulation of ELTD1 in tumor-associated endothelial cells, with a higher expression correlating with favorable prognosis. Importantly, ELTD1 silencing impairs endothelial sprouting and vessel formation in vitro and in vivo, drastically reducing tumor growth and greatly improving survival. Collectively, these results provide insight into the regulation of tumor angiogenesis and highlight ELTD1 as key player in blood vessel formation.
Collapse
Affiliation(s)
- Massimo Masiero
- Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, John Radcliffe Hospital, Headington, Oxford OX3 9DU, UK
- Cancer Research UK Department of Oncology, Weatherall Institute of Molecular Medicine, Oxford OX3 9DS, UK
| | - Filipa Costa Simões
- MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, Oxford OX3 9DS, UK
- Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford OX1 3QX, UK
| | - Hee Dong Han
- Department of Gynecologic Oncology, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
- Center for RNAi and Non-Coding RNA, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
| | - Cameron Snell
- Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, John Radcliffe Hospital, Headington, Oxford OX3 9DU, UK
| | - Tessa Peterkin
- MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, Oxford OX3 9DS, UK
| | - Esther Bridges
- Cancer Research UK Department of Oncology, Weatherall Institute of Molecular Medicine, Oxford OX3 9DS, UK
| | - Lingegowda S. Mangala
- Department of Gynecologic Oncology, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
- Center for RNAi and Non-Coding RNA, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
| | - Sherry Yen-Yao Wu
- Department of Gynecologic Oncology, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
| | - Sunila Pradeep
- Department of Gynecologic Oncology, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
| | - Demin Li
- Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, John Radcliffe Hospital, Headington, Oxford OX3 9DU, UK
| | - Cheng Han
- Cancer Research UK Department of Oncology, Weatherall Institute of Molecular Medicine, Oxford OX3 9DS, UK
| | - Heather Dalton
- Department of Gynecologic Oncology, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
| | - Gabriel Lopez-Berestein
- Center for RNAi and Non-Coding RNA, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
- Department of Cancer Biology, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
- Department of Experimental Therapeutics, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
| | - Jurriaan B. Tuynman
- Department of Colorectal Surgery, John Radcliffe Hospital, Headington, Oxford OX3 9DU, UK
| | - Neil Mortensen
- Department of Colorectal Surgery, John Radcliffe Hospital, Headington, Oxford OX3 9DU, UK
| | - Ji-Liang Li
- Cancer Research UK Department of Oncology, Weatherall Institute of Molecular Medicine, Oxford OX3 9DS, UK
| | - Roger Patient
- MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, Oxford OX3 9DS, UK
| | - Anil K. Sood
- Department of Gynecologic Oncology, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
- Center for RNAi and Non-Coding RNA, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
- Department of Cancer Biology, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
| | - Alison H. Banham
- Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, John Radcliffe Hospital, Headington, Oxford OX3 9DU, UK
| | - Adrian L. Harris
- Cancer Research UK Department of Oncology, Weatherall Institute of Molecular Medicine, Oxford OX3 9DS, UK
- Corresponding author
| | - Francesca M. Buffa
- Cancer Research UK Department of Oncology, Weatherall Institute of Molecular Medicine, Oxford OX3 9DS, UK
- Corresponding author
| |
Collapse
|
9
|
Kutschera S, Weber H, Weick A, De Smet F, Genove G, Takemoto M, Prahst C, Riedel M, Mikelis C, Baulande S, Champseix C, Kummerer P, Conseiller E, Multon MC, Heroult M, Bicknell R, Carmeliet P, Betsholtz C, Augustin HG. Differential Endothelial Transcriptomics Identifies Semaphorin 3G as a Vascular Class 3 Semaphorin. Arterioscler Thromb Vasc Biol 2011; 31:151-9. [DOI: 10.1161/atvbaha.110.215871] [Citation(s) in RCA: 54] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
Objective—
To characterize the role of a vascular-expressed class 3 semaphorin (semaphorin 3G [Sema3G]).
Methods and Results—
Semaphorins have been identified as axon guidance molecules. Yet, they have more recently also been characterized as attractive and repulsive regulators of angiogenesis. Through a transcriptomic screen, we identified Sema3G as a molecule of angiogenic endothelial cells. Sema3G-deficient mice are viable and exhibit no overt vascular phenotype. Yet, LacZ expression in the Sema3G locus revealed intense arterial vascular staining in the angiogenic vasculature, starting at E9.5, which was detectable throughout adolescence and downregulated in adult vasculature. Sema3G is expressed as a full-length 100-kDa secreted molecule that is processed by furin proteases to yield 95- and a 65-kDa Sema domain–containing subunits. Full-length Sema3G binds to NP2, whereas processed Sema3G binds to NP1 and NP2. Expression profiling and cellular experiments identified autocrine effects of Sema3G on endothelial cells and paracrine effects on smooth muscle cells.
Conclusion—
Although the mouse knockout phenotype suggests compensatory mechanisms, the experiments identify Sema3G as a primarily endothelial cell–expressed class 3 semaphorin that controls endothelial and smooth muscle cell functions in autocrine and paracrine manners, respectively.
Collapse
Affiliation(s)
- Simone Kutschera
- From Vascular Oncology and Metastasis (S.K., A.W., C.P., M.R., C.M., M.H., and H.G.A.), German Cancer Research Center Heidelberg (DKFZ-ZMBH Alliance), Heidelberg, Germany; Vascular Biology and Tumor Angiogenesis (S.K., A.W., C.P., M.H., and H.G.A.), Medical Faculty Mannheim (CBTM), Heidelberg University, Heidelberg, Germany; the Department of Vascular Biology and Angiogenesis Research (H.W., P.K., and H.G.A.), Tumor Biology Center, Freiburg, Germany; the Department for Transgene Technology and Gene
| | - Holger Weber
- From Vascular Oncology and Metastasis (S.K., A.W., C.P., M.R., C.M., M.H., and H.G.A.), German Cancer Research Center Heidelberg (DKFZ-ZMBH Alliance), Heidelberg, Germany; Vascular Biology and Tumor Angiogenesis (S.K., A.W., C.P., M.H., and H.G.A.), Medical Faculty Mannheim (CBTM), Heidelberg University, Heidelberg, Germany; the Department of Vascular Biology and Angiogenesis Research (H.W., P.K., and H.G.A.), Tumor Biology Center, Freiburg, Germany; the Department for Transgene Technology and Gene
| | - Anja Weick
- From Vascular Oncology and Metastasis (S.K., A.W., C.P., M.R., C.M., M.H., and H.G.A.), German Cancer Research Center Heidelberg (DKFZ-ZMBH Alliance), Heidelberg, Germany; Vascular Biology and Tumor Angiogenesis (S.K., A.W., C.P., M.H., and H.G.A.), Medical Faculty Mannheim (CBTM), Heidelberg University, Heidelberg, Germany; the Department of Vascular Biology and Angiogenesis Research (H.W., P.K., and H.G.A.), Tumor Biology Center, Freiburg, Germany; the Department for Transgene Technology and Gene
| | - Frederik De Smet
- From Vascular Oncology and Metastasis (S.K., A.W., C.P., M.R., C.M., M.H., and H.G.A.), German Cancer Research Center Heidelberg (DKFZ-ZMBH Alliance), Heidelberg, Germany; Vascular Biology and Tumor Angiogenesis (S.K., A.W., C.P., M.H., and H.G.A.), Medical Faculty Mannheim (CBTM), Heidelberg University, Heidelberg, Germany; the Department of Vascular Biology and Angiogenesis Research (H.W., P.K., and H.G.A.), Tumor Biology Center, Freiburg, Germany; the Department for Transgene Technology and Gene
| | - Guillem Genove
- From Vascular Oncology and Metastasis (S.K., A.W., C.P., M.R., C.M., M.H., and H.G.A.), German Cancer Research Center Heidelberg (DKFZ-ZMBH Alliance), Heidelberg, Germany; Vascular Biology and Tumor Angiogenesis (S.K., A.W., C.P., M.H., and H.G.A.), Medical Faculty Mannheim (CBTM), Heidelberg University, Heidelberg, Germany; the Department of Vascular Biology and Angiogenesis Research (H.W., P.K., and H.G.A.), Tumor Biology Center, Freiburg, Germany; the Department for Transgene Technology and Gene
| | - Minoru Takemoto
- From Vascular Oncology and Metastasis (S.K., A.W., C.P., M.R., C.M., M.H., and H.G.A.), German Cancer Research Center Heidelberg (DKFZ-ZMBH Alliance), Heidelberg, Germany; Vascular Biology and Tumor Angiogenesis (S.K., A.W., C.P., M.H., and H.G.A.), Medical Faculty Mannheim (CBTM), Heidelberg University, Heidelberg, Germany; the Department of Vascular Biology and Angiogenesis Research (H.W., P.K., and H.G.A.), Tumor Biology Center, Freiburg, Germany; the Department for Transgene Technology and Gene
| | - Claudia Prahst
- From Vascular Oncology and Metastasis (S.K., A.W., C.P., M.R., C.M., M.H., and H.G.A.), German Cancer Research Center Heidelberg (DKFZ-ZMBH Alliance), Heidelberg, Germany; Vascular Biology and Tumor Angiogenesis (S.K., A.W., C.P., M.H., and H.G.A.), Medical Faculty Mannheim (CBTM), Heidelberg University, Heidelberg, Germany; the Department of Vascular Biology and Angiogenesis Research (H.W., P.K., and H.G.A.), Tumor Biology Center, Freiburg, Germany; the Department for Transgene Technology and Gene
| | - Maria Riedel
- From Vascular Oncology and Metastasis (S.K., A.W., C.P., M.R., C.M., M.H., and H.G.A.), German Cancer Research Center Heidelberg (DKFZ-ZMBH Alliance), Heidelberg, Germany; Vascular Biology and Tumor Angiogenesis (S.K., A.W., C.P., M.H., and H.G.A.), Medical Faculty Mannheim (CBTM), Heidelberg University, Heidelberg, Germany; the Department of Vascular Biology and Angiogenesis Research (H.W., P.K., and H.G.A.), Tumor Biology Center, Freiburg, Germany; the Department for Transgene Technology and Gene
| | - Constantinos Mikelis
- From Vascular Oncology and Metastasis (S.K., A.W., C.P., M.R., C.M., M.H., and H.G.A.), German Cancer Research Center Heidelberg (DKFZ-ZMBH Alliance), Heidelberg, Germany; Vascular Biology and Tumor Angiogenesis (S.K., A.W., C.P., M.H., and H.G.A.), Medical Faculty Mannheim (CBTM), Heidelberg University, Heidelberg, Germany; the Department of Vascular Biology and Angiogenesis Research (H.W., P.K., and H.G.A.), Tumor Biology Center, Freiburg, Germany; the Department for Transgene Technology and Gene
| | - Sylvain Baulande
- From Vascular Oncology and Metastasis (S.K., A.W., C.P., M.R., C.M., M.H., and H.G.A.), German Cancer Research Center Heidelberg (DKFZ-ZMBH Alliance), Heidelberg, Germany; Vascular Biology and Tumor Angiogenesis (S.K., A.W., C.P., M.H., and H.G.A.), Medical Faculty Mannheim (CBTM), Heidelberg University, Heidelberg, Germany; the Department of Vascular Biology and Angiogenesis Research (H.W., P.K., and H.G.A.), Tumor Biology Center, Freiburg, Germany; the Department for Transgene Technology and Gene
| | - Catherine Champseix
- From Vascular Oncology and Metastasis (S.K., A.W., C.P., M.R., C.M., M.H., and H.G.A.), German Cancer Research Center Heidelberg (DKFZ-ZMBH Alliance), Heidelberg, Germany; Vascular Biology and Tumor Angiogenesis (S.K., A.W., C.P., M.H., and H.G.A.), Medical Faculty Mannheim (CBTM), Heidelberg University, Heidelberg, Germany; the Department of Vascular Biology and Angiogenesis Research (H.W., P.K., and H.G.A.), Tumor Biology Center, Freiburg, Germany; the Department for Transgene Technology and Gene
| | - Petra Kummerer
- From Vascular Oncology and Metastasis (S.K., A.W., C.P., M.R., C.M., M.H., and H.G.A.), German Cancer Research Center Heidelberg (DKFZ-ZMBH Alliance), Heidelberg, Germany; Vascular Biology and Tumor Angiogenesis (S.K., A.W., C.P., M.H., and H.G.A.), Medical Faculty Mannheim (CBTM), Heidelberg University, Heidelberg, Germany; the Department of Vascular Biology and Angiogenesis Research (H.W., P.K., and H.G.A.), Tumor Biology Center, Freiburg, Germany; the Department for Transgene Technology and Gene
| | - Emmanuel Conseiller
- From Vascular Oncology and Metastasis (S.K., A.W., C.P., M.R., C.M., M.H., and H.G.A.), German Cancer Research Center Heidelberg (DKFZ-ZMBH Alliance), Heidelberg, Germany; Vascular Biology and Tumor Angiogenesis (S.K., A.W., C.P., M.H., and H.G.A.), Medical Faculty Mannheim (CBTM), Heidelberg University, Heidelberg, Germany; the Department of Vascular Biology and Angiogenesis Research (H.W., P.K., and H.G.A.), Tumor Biology Center, Freiburg, Germany; the Department for Transgene Technology and Gene
| | - Marie-Christine Multon
- From Vascular Oncology and Metastasis (S.K., A.W., C.P., M.R., C.M., M.H., and H.G.A.), German Cancer Research Center Heidelberg (DKFZ-ZMBH Alliance), Heidelberg, Germany; Vascular Biology and Tumor Angiogenesis (S.K., A.W., C.P., M.H., and H.G.A.), Medical Faculty Mannheim (CBTM), Heidelberg University, Heidelberg, Germany; the Department of Vascular Biology and Angiogenesis Research (H.W., P.K., and H.G.A.), Tumor Biology Center, Freiburg, Germany; the Department for Transgene Technology and Gene
| | - Melanie Heroult
- From Vascular Oncology and Metastasis (S.K., A.W., C.P., M.R., C.M., M.H., and H.G.A.), German Cancer Research Center Heidelberg (DKFZ-ZMBH Alliance), Heidelberg, Germany; Vascular Biology and Tumor Angiogenesis (S.K., A.W., C.P., M.H., and H.G.A.), Medical Faculty Mannheim (CBTM), Heidelberg University, Heidelberg, Germany; the Department of Vascular Biology and Angiogenesis Research (H.W., P.K., and H.G.A.), Tumor Biology Center, Freiburg, Germany; the Department for Transgene Technology and Gene
| | - Roy Bicknell
- From Vascular Oncology and Metastasis (S.K., A.W., C.P., M.R., C.M., M.H., and H.G.A.), German Cancer Research Center Heidelberg (DKFZ-ZMBH Alliance), Heidelberg, Germany; Vascular Biology and Tumor Angiogenesis (S.K., A.W., C.P., M.H., and H.G.A.), Medical Faculty Mannheim (CBTM), Heidelberg University, Heidelberg, Germany; the Department of Vascular Biology and Angiogenesis Research (H.W., P.K., and H.G.A.), Tumor Biology Center, Freiburg, Germany; the Department for Transgene Technology and Gene
| | - Peter Carmeliet
- From Vascular Oncology and Metastasis (S.K., A.W., C.P., M.R., C.M., M.H., and H.G.A.), German Cancer Research Center Heidelberg (DKFZ-ZMBH Alliance), Heidelberg, Germany; Vascular Biology and Tumor Angiogenesis (S.K., A.W., C.P., M.H., and H.G.A.), Medical Faculty Mannheim (CBTM), Heidelberg University, Heidelberg, Germany; the Department of Vascular Biology and Angiogenesis Research (H.W., P.K., and H.G.A.), Tumor Biology Center, Freiburg, Germany; the Department for Transgene Technology and Gene
| | - Christer Betsholtz
- From Vascular Oncology and Metastasis (S.K., A.W., C.P., M.R., C.M., M.H., and H.G.A.), German Cancer Research Center Heidelberg (DKFZ-ZMBH Alliance), Heidelberg, Germany; Vascular Biology and Tumor Angiogenesis (S.K., A.W., C.P., M.H., and H.G.A.), Medical Faculty Mannheim (CBTM), Heidelberg University, Heidelberg, Germany; the Department of Vascular Biology and Angiogenesis Research (H.W., P.K., and H.G.A.), Tumor Biology Center, Freiburg, Germany; the Department for Transgene Technology and Gene
| | - Hellmut G. Augustin
- From Vascular Oncology and Metastasis (S.K., A.W., C.P., M.R., C.M., M.H., and H.G.A.), German Cancer Research Center Heidelberg (DKFZ-ZMBH Alliance), Heidelberg, Germany; Vascular Biology and Tumor Angiogenesis (S.K., A.W., C.P., M.H., and H.G.A.), Medical Faculty Mannheim (CBTM), Heidelberg University, Heidelberg, Germany; the Department of Vascular Biology and Angiogenesis Research (H.W., P.K., and H.G.A.), Tumor Biology Center, Freiburg, Germany; the Department for Transgene Technology and Gene
| |
Collapse
|